NASDAQ and Taiwania Capital lead a $20m Series C-1 round in Nanolive.

NASDAQ and Taiwania Capital lead a $20m Series C-1 round in Nanolive, a live cell imaging and analysis company, with participation from Swisscom Ventures. “Life Sciences are undergoing a fundamental transformation, and Nanolive is at the heart of it. We are honored to receive an investment from such an impressive group of investors who are excited to support us in our goal to transform the discovery and development of therapeutics. With this fundraising, we believe Nanolive is well positioned to drive significant growth of our Digital Assay solutions and is at the leading edge of this global bioeconomy gold rush. We are selling the best picks and shovels for live cell solutions," Yann Cotte, Nanolive CEO and Co-Founder.